A PstI restriction fragment length polymorphism in the 5' untranslated region of DRD4 is not associated with schizophrenia.
We detected a PstI restriction fragment length polymorphism in the 5'-non-coding region of the dopamine D4 receptor gene (DRD4), making it the seventh known polymorphism for DRD4. DNA polymorphisms in the putative regulatory region of DRD4 are of interest because of the reported six-fold increase in D4 receptors in post-mortem schizophrenic brain tissue [Seeman P, Guan HC, Van Tol HHM (1993) Nature, 365, 441-445]. We found no difference in the PstI allele frequencies between DSM-III-R schizophrenia patients (0.76 and 0.24, n = 41), and matched control Caucasians (0.77 and 0.23, n = 46). The PstI DRD4 polymorphism has potential use in linkage and association studies with neuropsychiatric and cardiovascular disorders.
Paterson
A D
AD
Neurogenetics Section, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
Ying
D J
DJ
Petronis
A
A
Schoots
O
O
Lieberman
J A
JA
Van Tol
H H
HH
Kennedy
J L
JL
D015252:Deoxyribonucleases, Type II Site-Specific; D015870:Gene Expression; D006801:Humans; D012150:Polymorphism, Restriction Fragment Length; D014176:Protein Biosynthesis; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis / Q000235:genetics*; D050638:Receptors, Dopamine D4; D012045:Regulatory Sequences, Nucleic Acid; D012559:Schizophrenia / Q000235:genetics*
C493599:DRD4 protein, human; D017448:Receptors, Dopamine D2; D050638:Receptors, Dopamine D4; C024388:CTGCAG-specific type II deoxyribonucleases; D015252:Deoxyribonucleases, Type II Site-Specific